Independent Director's 2025 Annual Performance Report
To the Shareholders and Representatives:
As an independent director of Shenzhen Highstar Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), in 2025, I strictly followed the provisions of the "Company Law," "Administrative Measures for Independent Directors of Listed Companies," "Independent Director Work System," and "Articles of Association," as well as relevant laws and regulations. I attended relevant meetings, diligently reviewed all proposals, and faithfully and diligently performed my duties as an independent director, effectively safeguarding the legitimate rights and interests of the Company and its shareholders, especially small and medium shareholders. The following is a brief report of my work in 2025:
I. Basic Information of Independent Director
I am Huang Peng, a Chinese national, holding a Ph.D. and a professor of accounting. I have served as Associate Professor, Professor, Department Head, and Doctoral Supervisor of Accounting at Soochow University. I have previously served as an independent director for Jiangsu Yaxing Chemical Fiber Co., Ltd., Jiangsu Juhui Microfiber Technology Group Co., Ltd., and Suzhou Wanxiang Technology Co., Ltd. I am currently the Dean of the Research Institute for New Era Entrepreneurs at Soochow University, an independent director of Suzhou Kelida Decoration Co., Ltd., and an independent director of the Company.
As an independent director of the Company, I meet the relevant requirements for independence of independent directors stipulated in the "Administrative Measures for Independent Directors of Listed Companies" and the "Shenzhen Stock Exchange Main Board Listed Company Self-Regulatory Supervision Guidelines No. 1 – Standardized Operation of Main Board Listed Companies," and there are no circumstances that affect my independence.
II. Performance of Duties by Independent Director in 2025
(I) Attendance at Board of Directors and Shareholders' Meetings in 2025
During the reporting period, the Company held a total of 2 shareholders' meetings and 6 board of directors' meetings. My attendance is as follows:
| Item | Number of times required to attend | Number of times attended in person | Number of times attended via communication | Number of times entrusted to attend | Number of times absent | Whether personally attended board meetings for two consecutive times | Number of times attended shareholders' meetings |
|---|---|---|---|---|---|---|---|
| During the reporting period | 6 | 0 | 6 | 0 | 0 | No | 2 |
When attending board of directors' meetings as an independent director, I diligently reviewed each proposal, actively participated in discussions, and offered reasonable suggestions. I exercised my voting rights with prudence. I approved all proposals of the Company's board of directors and did not express any objections, opposition, or abstentions.
(II) Participation in Meetings of Board Committees and Independent Director Special Meetings in 2025
In 2025, I served as the Chairman of the Audit Committee and a member of the Remuneration and Nomination Committee.
As the Chairman of the Audit Committee, I actively participated in Audit Committee meetings. During the reporting period, I was required to attend 5 Audit Committee meetings and attended all 5. I reviewed the Company's annual reports, internal audit reports, internal control evaluation reports, profit distribution plans, and the re-appointment of accounting firms.